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Background: Metabolic syndrome (MetS) and depression have become two prevalent diseases worldwide, whose
interaction needs further investigation. Dietary treatment for weight loss in patients with MetS may improve
depressive manifestations, however, the precise interactive pathways remain uncertain. Therefore, the aim of this
study was to examine the effects of a hypocaloric diet designed to reduce MetS features on self-perceived
depression and the possible underlying factors.
Methods: Sixty subjects (Age: 50 ± 1 y; BMI: 36.1 ± 0.6 kg/m2) with MetS were selected from the RESMENA study
(control and intervention) after they completed the 6-months hypocaloric treatment and rated for depressive
symptoms using the Beck Depression Inventory (BDI). Anthropometric and biochemical measurements including
leptin, C-reactive protein (CRP) and insulin levels were evaluated.
Results: Depressive symptoms decreased during the weight loss intervention, with no differences between both
dietary groups (control group −4.2 ± 0.8 vs RESMENA group −3.2 ± 0.6, P = 0.490). The number of criteria of the
MetS was higher among subjects with more somatic-related depressive symptoms at baseline (B = 1.032, P-trend =
0.017). After six months of dietary treatment, body weight decreased in all subjects (−8.7%; confidence interval
(95% CI) = 7.0-9.7) and also self-perceived depression (−37.9%; 95% CI = 2.7-4.9), as well as circulating leptin (−20.1%;
95% CI = 1.8-6.8), CRP (−42.8%; 95% CI = 0.6-3.0) and insulin (−37.7%; 95% CI = 4.1-7.2) concentrations. The decrease
in BDI was significantly associated with declines in body fat mass (B = 0.34, 95% CI = 0.11-0.56) and also with the
decrease in leptin (B = 0.16, 95% CI = 0.04-0.28) and CRP (B = 0.24, 95% CI = 0.01-0.46) concentrations.
Conclusions: The decrease in depressive manifestations after a weight loss intervention was related with adiposity,
CRP and leptin in subjects with MetS.
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The metabolic Syndrome (MetS) is defined as a cluster
of major cardiovascular risk factors including central
obesity, glucose intolerance, hypertension and serum
lipid disorders, whose prevalence is rapidly increasing
worldwide [1,2]. Similarly, certain MetS features such
as excessive adiposity, glucose intolerance and dyslip-
idemia, have been associated with depression [3],
which is considered the fourth leading cause of disease
burden in the world [4].
Because of the high prevalence and public health im-
plications of both depression and MetS, the potential
association between them has recently received much
attention [5,6]. However, the exact interactive path-
ways between these diseases still remain uncertain, al-
though they seem to be bidirectional and predisposed
by both biochemical and behavioral mediators [6]. De-
pression involves dysregulation of the adrenocortical
and autonomic nervous systems, which could increase
MetS risk by favoring abdominal fat accumulation and
insulin resistance [6]. Furthermore, subjects with MetS
present increased levels of inflammatory cytokines and
leptin resistance. Thus, C-reactive protein (CRP), a
serum marker of systemic inflammation, has been a
frequently investigated inflammatory marker in subjects
with MetS [7]. Also, chronic inflammation could be
involved in mood disorders, as a positive relationship
between depression and CRP has been reported [8]. Re-
garding the association between depression and leptin,
an adipokine mainly secreted by adipocytes with a key
role in energy regulation, it seems that resistance to this
hormone may contribute to higher depression rates in
obese subjects [9].
Various strategies have been proposed to counteract
MetS manifestations, including lifestyle (diet and exercise)
modification and drug therapy based on antihypertensives,
insulin sensitizers or therapies for dyslipidemia [10].
One of the most prescribed lifestyle changes is dietary
treatment for weight loss, where the Mediterranean
diet has been proven to be a useful tool to improve
both MetS and depression symptoms [11,12]. Also, the
psychological effects of weight loss approaches have
been a matter of controversy, mainly regarding how
changes in body weight correlate with depressive symp-
toms [13].
This research is based on a subsample of the
RESMENA-S study [14-17], a randomized, controlled
intervention study that aims to reduce MetS features
using a hypocaloric diet during six months. In this art-
icle, we hypothesized that a hypocaloric treatment de-
signed to reduce MetS features produces a positive
effect on depressive symptoms, and we sought to ex-
plore the possible underlying mechanisms and interac-
tions of this effect.Subjects and methods
Subjects
A total of ninety-three subjects (52 M/41 F) with a body
mass index (BMI) of 36.1 ± 0.6 kg/m2 aged 50 ± 1 years di-
agnosed with MetS according to the IDF cut-offs [18]
started the weight loss treatment. The inclusion and exclu-
sion criteria have been previously reported [14-17], but it
should be pointed out that subjects following antidepres-
sant treatment were excluded as well as those with past
mood disorders, including eating disorders. Also, vitamin
or mineral supplements were not allowed.
After six months of weight loss intervention there
were twenty-six dropouts due to loss to follow-up or
consent withdrawal. Seven of the sixty-seven partici-
pants that finished the study did not complete all the
Beck Depression Inventories (BDI). Therefore the
present longitudinal study assessed the data from those
60 subjects (age: 50 ± 1 y.; 38 M/22 F), who completed
the BDI in the three main visits (baseline, after two
months and at the end of the study), as described in
the study flowchart (Figure 1).
In the RESMENA study, the CONSORT 2010 guide-
lines [19] were followed, and all the volunteers signed
written informed consent before participating in the
intervention study. The study protocol was performed
in accordance with the ethical guidelines of the Declar-
ation of Helsinki, and was approved by the Research
Ethics Committee of the University of Navarra (ref.
065/2009).Study protocol
The current study is based on a subsample of the
RESMENA-S study, a randomized controlled interven-
tion study aiming to improve clinical criteria and bio-
markers associated with MetS through a dietary
strategy for weight loss during six months. Briefly, par-
ticipants were randomly assigned to follow one of the
two energy-restricted diets, the control diet [20] or the
RESMENA diet [14-17], both with the same energy re-
striction (−30% energy of the calculated requirements)
by using the “random between 1 and 2” function in the
Microsoft Office Excel 2003 software (Microsoft Iberica,
Spain). The diets composition, as well as the different
48-h dietary records, were analyzed by the DIAL (Alce
Ingenieria, Madrid, Spain) software and described else-
where [16,17].
The volunteers were asked to maintain their usual
physical activity, which was controlled by a 24-h phys-
ical activity questionnaire at the beginning and at the
end of the study [21]. A psychological control using the
BDI questionnaire was carried out at the main time
points previously mentioned. More aspects of this inter-
vention study have been previously detailed [14-17].
Figure 1 Flowchart of the randomized and controlled dietary intervention for adults with MetS. The 26 volunteers that dropped out did
so for personal reasons not related to the study. Abbreviations: BDI, Beck Depression Inventory; IDF, International Diabetes Federation; MetS,
Metabolic Syndrome.
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Anthropometric and body composition measurements
were taken following standardized procedures previously
described [15-17].
Serum glucose, total cholesterol, HDL-cholesterol, tri-
glycerides and free fatty acids serum concentrations
were measured in an autoanalyser Pentra C-200 (HOR-
IBA ABX, Madrid, Spain) with specific kits. Insulin con-
centrations were determined by an enzyme-linked
immunosorbent assay (ELISA) kit (Mercodia, Uppsala,
Sweden) using an automated analyser system (Triturus,
Grifols, Barcelona). Serum insulin resistance was esti-
mated by the Homeostasis Model Assessment Index
(HOMA-IR) calculated with the following formula:
HOMA-IR = fasting glucose (mmol/L)xfasting insulin
(mU/L)]/22.5 [22].
Plasma concentrations of CRP was assessed by an
Immunodiagnostic AG kit (Bensheim, Germany) using
an automated analyser system (Triturus, Grifols, Barcelona).
Serum concentrations of leptin were measured using
a RIA-based method (Diagnostic Products Corp., Los
Angeles, CA).Assessment of depressive symptoms
Symptoms of depression were assessed at the main three
time points of the study (baseline, after two months and at
the end of the study) using the Spanish version of the BDI
[23], which is considered a validated and reliable measure
of depressive symptoms [24,25]. A score ≥ 10 reflects mod-
erate depressive symptoms. The BDI questionnaire was di-
vided into two subscales: the cognitive and the somatic
symptom components. Question number 19 of the test,
relating to weight loss, was discarded in some of the
analyses given that losing weight is considered a depres-
sive symptom, but our volunteers estimated it a positive
aspect because they were enrolled in a weight loss treat-
ment program [17].
Statistical analyses
The sample size for the main study (the RESMENA
study) was calculated based on previous findings [26],
where the mean difference in the waist circumference
was 4.3 cm and the standard deviation (SD) was 6.8 cm.
To test the hypothesis of the present substudy and tak-
ing into account previous studies [27], a sample size of
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nificant difference in the reduction of BDI score (2.2 ± 2.5
units), with an alpha error of 5% and a power of 90%.
The main results were summarized as mean ± SEM.
Following published studies, the BDI score was analyzed
as a continuous variable [9]. The Kolmogorow-Smirnov
and the Shapiro Wilk test were used to analyze the nor-
mality of the measured variables. Analysis of covariance
(ANCOVA) was used to assess changes between dietary
treatments for the main dietary variables of the study, with
sex and age as covariates. Changes in anthropometric and
biochemical variables, as well as changes in the BDI ques-
tionnaire and physical activity level, were evaluated by
repeated-measures ANOVA (three time points) or by using
the nonparametric Friedman test when variables followed
a non-normal distribution. Also, the effect of diet on these
variables as well as the time-diet interaction was taken in
consideration. A Bonferroni post hoc multiple comparison
analysis was used when appropriate.
Tests of linear trend by increasing MetS criteria were
conducted by assigning the mean value of BDI (somatic
and cognitive questions separately) and modeling these
values as a continuous variable. The changes in the cogni-
tive and somatic questions (6 months – baseline) were
assessed by ANCOVA with sex, age and dietary group as
covariates. The association between changes (6 months –
baseline) in BDI questionnaire and changes (6 months –
baseline) total fat mass (kg) was analyzed using multi-
variable linear regression analysis adjusted by sex, age
and dietary group. For the association between changes
in CRP, leptin and insulin with changes in BDI score
three models were constructed: Model 1 included sex, age
and dietary group variables. Model 2 included model 1
additionally adjusted for changes in activity level, and
model 3 consisted of model 1 plus changes in total fat
mass (kg). All statistical analyses were carried out using
SPSS 15.0 software for Windows (SPSS Ibérica, Madrid,
Spain). Differences were considered statistically significant
at P < 0.05.
Results
The main dietary characteristics of the two prescribed
diets were compared showing that, as expected, the
RESMENA group consumed more protein than the
Control group during the dietary treatment. Moreover,
the RESMENA group showed a greater decrease in lipid
intake, but lower intake of ω3 PUFA (Table 1). After six
months of dietary treatment, subjects’ anthropometric and
biochemical variables improved significantly, observing a
mean weight loss of 8.4 ± 1.2 kg (P < 0.001). However,
there were no differences (P ≥ 0.10) between both dietary
intervention groups in neither anthropometric nor bio-
chemical variables, as well as activity level of the volun-
teers. Also, both Control and RESMENA diets proved tobe equally effective on improving the BDI score (Table 2).
Therefore, as no significant differences between dietary
groups were found in any of the variables analyzed in this
study, henceforth the two groups were merged and ana-
lyzed together as a unique experimental group.
The comparative analysis between completers (n = 62)
and dropouts (n = 25) concerning BDI score available at
baseline, showed no significant differences (P = 0.255).
Nonetheless, completers evidenced a lower mean value
of BDI score at baseline (7.6 ± 0.7) in relation to those
who did not finish the dietary treatment (9.3 ± 1.0).
The total number of subjects presenting a BDI score ≥10
units at baseline was 25% (9 M/6 F). After two months of
weight loss treatment, this number decreased to 8.3% of
the volunteers (3 M/2 F). At the end of the study (6 months
later), only 6.6% of the subjects reported a BDI score ≥ 10
(2 M/2 F).
A test of linear trend revealed that the higher the num-
ber of components of MetS according to IDF criteria (3, 4
or 5 components), the higher somatic BDI score at base-
line. Interestingly, this association was not observed in the
cognitive questions of the questionnaire (Figure 2).
In turn, losing more weight led to greater reductions
(P < 0.013) in depressive symptoms (more weight loss
ΔBDI = −5.2 ± 0.9; vs less weight loss ΔBDI = −2.5 ± 0.6).
As expected, when we compared all the somatic-related
questions separately between both groups (more weight
loss vs less weight loss), significant differences were ob-
served in the weight loss question, but also in the fatig-
ability and loss of libido questions. Subjects reported
losing more weight at 6 months than at baseline in the
BDI questionnaire, hence the score of this question was
higher at the end of the study. However, subjects who
lost more weight did not show a greater reduction in
the cognitive-related questions compared to individuals
with lower body weight change (Figure 3).
Additionally, a positive association between changes in
depressive symptoms and changes in kg of total fat mass
was observed (Figure 4). We also found an association be-
tween changes in BDI score during the intervention period
and changes in CRP, leptin and insulin levels. Further ad-
justment for body fat change eliminated the relation be-
tween depressive symptoms and insulin levels, however,
the association of BDI with CRP and leptin remained sta-
tistically significant (Table 3).
Discussion
The present study reports an association of the reduction
in depressive manifestations with the decrease in CRP and
leptin after a dietary treatment for weight loss in subjects
with MetS. Moreover, the reduction in fat mass was also
involved in the decrease of depressive symptoms, but it
was not implicated in the association of this variable with
CRP and leptin. Previous investigations have reported a
Table 1 Comparison of the two dietary treatments, control diet and RESMENA diet
Control group (n = 32) RESMENA group (n = 28) P value
Dietary intake Baseline 6 months Baseline 6 months
Total energy intake, Kcal/d 2108 ± 69 1535 ± 54* 2279 ± 99 1573 ± 72* 0.105
Proteins, g/d 95.9 ± 3.5 66.9 ± 3.4* 95.6 ± 3.4 79.3 ± 3.4* 0.012
Carbohydrates, g /d 187.3 ± 9.8 142.6 ± 8.1* 196.4 ± 11.5 138.9 ± 6.2* 0.579
Lipids, g/d 94.7 ± 4.3 69.1 ± 2.9* 108.7 ± 5.9 67.0 ± 3.8* 0.026
Fiber, g/d 21.4 ± 1.8 17.8 ± 1.7 22.6 ± 1.1 19.4 ± 1.2 0.748
Glycemic load 106.6 ± 8.6 72.8 ± 5.8* 112.1 ± 7.4 69.7 ± 5.1* 0.491
ω3 PUFAs , g/d 0.28 ± 0.01 0.28 ± 0.02 0.35 ± 0.16 0.08 ± 0.02* 0.002
Meal frequency, meals/d 4.6 ± 0.1 4.5 ± 0.1 5.5 ± 0.2 5.9 ± 0.2 0.100
Data are mean ± SEM, n = 60. *Different from baseline in each dietary group, P <0.05; P value: comparison between dietary group differences (6 months-baseline).
Abbreviations: ω3 PUFAs, omega-3 polyunsaturated fatty acids.
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treatment [13,28], however, this study specifically demon-
strates a relationship of the decrease in CRP and leptin
with the reduction in self-perceived depression in subjects
suffering MetS.
The domains of self-perceived depression were divided
in cognitive and somatic questions in order to better inter-
pret the primary cause of patient depression [29]. At base-
line, there was a ranked relationship between increasing
number of MetS components and a higher rate of somaticTable 2 Anthropometric and biochemical variables in adults w
Variables Baseline 2 months
Weight, kg 102.8 ± 2.2a 95.4 ± 2.1b
BMI, kg/m2 36.1 ± 0.6a 33.5 ± 0.5b
WC, cm 114.2 ± 1.6a 106.8 ± 1.5b
DXA measurements
Fat mass, kg 42.9 ± 1.2a 37.5 ± 1.2b
Muscle mass, kg 56.6 ± 1.5a 54.5 ± 1.4b
Biochemical variables
Cholesterol, mg/dL 219 ± 5a 197 ± 5b
Glucose, mg/dL 128 ± 5a 111 ± 3b
TG, mg/dL 195 ± 13a 146 ± 10b
FFA, mmol/L 0.56 ± 0.21a 0.52 ± 0.24a,b
CRP, mg/L 4.3 ± 0.7 a 3.1 ± 0.4a,b
HOMA index, mM/L 4.9 ± 0.4a 2.8 ± 0.3b
Leptin, ng/mL 21.5 ± 2.1a 14.5 ± 1.5c
Insulin, μU/mL 15.4 ± 1.1a 9.7 ± 0.9b
BDI questionnaire 7.6 ± 0.8a 4.4 ± 0.6b
Activity level2 1.6 ± 0.1 1.6 ± 0.1
Values are mean ± SEM n= 57-60. Effects of time, diet (control diet vs RESMENA diet) and
test. Values in a row with different superscript letters (a, b, c) are significantly different, P<
Depression Inventory; BMI, body mass index; CRP, C-reactive protein; DXA, dual-energy X-
WC, waist circumference.
1P-value based on non-parametric Friedman test compared the three time points o
2Average daily exercise calculated by twenty-four physical activity questionnaire.questions but not of cognitive components. These findings
were similar to those observed in a previous study also
based on self-reported BDI questionnaire [30].
Question number 19 of the BDI test, related to weight
loss, was apparently distorting the total BDI score. This
observation was confirmed because the weight loss was
associated with the decrease in body weight at the end of
the dietary treatment, showing that those subjects who
lost most weight, had a higher score on the weight loss
question of the test. Therefore, the weight loss questionith MetS
P value
6 months Time Diet TimexDiet
94.4 ± 2.2b < 0.001 0.834 0.666
33.2 ± 0.6b < 0.001 0.997 0.474
105.7 ± 1.6b < 0.001 0.999 0.102
36.3 ± 1.2c < 0.0011 0.469 0.432
54.8 ± 1.5b < 0.001 0.694 0.239
219 ± 5a < 0.001 0.568 0.751
116 ± 4b 0.0011 0.786 0.377
154 ± 12b < 0.0011 0.730 0.955
0.47 ± 0.20b 0.016 0.122 0.461
2.5 ± 0.4b 0.0051 0.597 0.183
3.0 ± 0.4b < 0.001 0.956 0.288
17.2 ± 1.9b < 0.001 0.816 0.837
9.6 ± 1.0b < 0.0011 0.964 0.634
3.8 ± 0.7c < 0.001 0.777 0.798
1.6 ± 0.1 0.154 0.697 0.184
time-diet interactions were analysed with repeated-measures ANOVA or Friedman
0.05 by Bonferroni post hoc test, being a > b> c. Abbreviations: BDI, Beck
ray absorptiometry; FFA, free fatty acids; MetS, Metabolic Syndrome; TG, triglycerides;
f the study.
Figure 2 Association between the number of MetS components assessed by IDF criteria and the BDI score at baseline. Values are mean ± SEM,
n= 60. BDI score divided by somatic and cognitive questions Abbreviations: BDI, Beck Depression Inventory; IDF, International Diabetes Federation.
Figure 3 Changes in BDI cognitive and somatic questions scores (6 months – baseline). n = 60. Range from −3 to 3. Subjects with MetS
were divided into more (≥median = −7.6 kg) or less (<the median = −7.6 kg) body weight change after the dietary treatment. Abbreviations: BDI,
Beck Depression Inventory; MetS, Metabolic Syndrome. *p < 0.05. **p < 0.010.
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Figure 4 Association between changes in BDI score and
changes in body fat (kg). Abbreviations: BDI, Beck Depression
Inventory. Adjusted by sex, age and dietary group. Changes
(6 months – baseline), n = 60.
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Moreover, the improvement in the fatigability and loss of
libido questions (somatic-related questions) might be con-
sidered as benefits of the weight loss.
Noteworthy, a positive association between decreases in
CRP values and reductions in depressive symptoms was
observed as has been reported in previous studies [8]. In-
flammation seems to be, in part, responsible for the linkTable 3 Association between changes in BDI score and
changes in CRP, leptin and insulin
Change in BDI score
Changes in: B 95% CI p
CRP mg/L
Unadjusted model 0.25 0.01 to 0.49 0.043
Model 1 0.27 0.03 to 0.51 0.029
Model 2 0.26 0.01 to 0.50 0.044
Model 3 0.28 0.06 to 0.51 0.015
Leptin ng/mL
Unadjusted model 0.18 0.07 to 0.29 0.002
Model 1 0.21 0.10 to 0.32 0.001
Model 2 0.22 0.08 to 0.36 0.012
Model 3 0.17 0.04 to 0.30 0.013
Insulin μU/mL
Unadjusted model 0.21 0.02 to 0.40 0.026
Model 1 0.25 0.07 to 0.42 0.006
Model 2 0.33 0.15 to 0.52 0.001
Model 3 0.18 −0.01 to 0.36 0.059
The table shows B coefficients (95% CI) and p-value. Changes (6 months-baseline),
n = 60. Abbreviation: BDI, Beck Depression Inventory; CRP, C-reactive protein.
Model 1: Adjusted by sex, age and dietary group. Model 2: Model 1
additionally adjusted for changes in activity level. Model 3: Model 1
additionally adjusted for changes in body fat (kg).between depressive symptoms and MetS. However, the
precise nature of this relationship is not clear [8]. Theoret-
ically, the association of leptin with depression may be
related both to its metabolic properties and neurobio-
logical activities [9]. Leptin affects cognition and mood in
the hippocampus, the cortex and other brain areas associ-
ated with cognition [9,31]. Obesity is related to higher
levels of circulating leptin reflecting, in part, an increased
formation of adipocytes, and causing leptin resistance in
some obese subjects. A positive association between the
decline in BDI score and the drop in leptin values was
found, in line with results from previous studies [9,32].
Furthermore, in an unadjusted model, a positive associ-
ation was noted between insulin and depressive symp-
toms, being this link well-established [33,34]. However,
this association was no longer statistically significant when
change in body fat was introduced in the model.
A previous weight loss intervention study showed that
depression scores at baseline predicted adherence to a
dietary treatment [28]. In accordance with this outcome, a
higher BDI score in drop-outs at baseline was observed,
although this value did not reach statistical significance. A
positive association between lower BDI score and de-
creases in body weight was found, which is in agreement
with previous studies [13]. In addition, there is some evi-
dence suggesting that adiposity is directly related with
depression [3]. In this study, the higher decrease in de-
pressive symptoms was noticeable in those participants
with a greater decline in total fat mass. Since adipose tis-
sue is known to secrete inflammatory cytokines and leptin
[35], it might be hypothesized that the decrease in body
fat mass may have contributed to reduce CRP and leptin
and subsequently decrease depressive symptoms.
Furthermore, the Mediterranean diet has been associated
with reduced prevalence and incidence of MetS and de-
pressive symptoms [11,12]. A healthy dietary pattern has
been associated with better mood [36] and diets rich in ω3
PUFA may decrease serum cytokine production and de-
pressive signs [37]. Also, an inverse association between
both vitamin D and vitamin C levels with depressive symp-
toms has been observed [38,39]. In this context, we have
previously shown that folate intake during this dietary
intervention was well correlated with the decrease in de-
pressive symptoms [17].
Because both MetS and depressive manifestations seem
to share several common mechanisms, it has been sug-
gested that the dietary recommendations for MetS might
be helpful for depression treatment [5]. The present study
strengthens this hypothesis, as the dietary treatment for
MetS manifestations also reduced depressive symptoms.
Moreover, several unhealthy lifestyle habits have been re-
lated with depressive symptoms, such as fast food con-
sumption, high fat intake or low physical activity [5,40]. In
this study, physical activity was not directly associated
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ous investigations [41].
The control diet based on the AHA guidelines is a
well-design strategy for weight loss [20], what may ex-
plain that no differences between dietary groups were
observed in the variables analyzed in this study. As both
dietary groups proved to be effective in reducing depres-
sive symptoms and no differences between them were
found, both groups were merged and analyzed together
as a unique experimental group. A longitudinal observa-
tional analysis comparing the BDI scores before and
after intervention was conducted, serving the volunteers
as their own control. The clear differences between the be-
ginning and the end of the study lend support to the
soundness of the analysis. One of the strengths of within-
subjects (paired) analyses is the reduction in error variance
associated with individual differences, which increases stat-
istical power. Moreover, in order to control the possible
confounding role of the intervention group, this variable
was included in the multiple-adjusted models investi-
gating the association of anthropometric and biochem-
ical variables with depressive manifestations in the
complete sample [17].
The study has some limitations. Firstly, depressive
symptoms were evaluated using a self-report question-
naire, the Beck Depression Inventory, which is not de-
signed as a diagnostic tool but as a screening method [24].
However, this test was chosen as it is widely recognized, it
has been shown to be valid for clinical assessment [25]
and it has previously been used to record depressive
symptoms in weight loss studies [13,28]. Secondly, this
study only aimed to evaluate the association between the
variables included and it cannot be determined any con-
clusions on causality between changes in body weight, fat
mass, leptin and CRP and changes in depressive symp-
toms. In addition, the prevalence of depressive symptoms
in our sample was low, which can be explained with the
fact that subjects presenting psychiatric disorders at en-
rollment were not allowed to participate in the study.
Also, the number of participants in this study is not very
high, but it may be proposed that type-II errors were over-
come since important statistical differences were found.Conclusions
In conclusion, this study shows an association of the re-
duction in depressive manifestations with CRP and lep-
tin in subjects with MetS after following a weight loss
treatment. Interestingly, the decrease in fat mass was
also related with the reduction of depressive symptoms.
More studies are needed to explore the mechanisms
underlying the MetS-depression relationship, which
may be decisive for the prevention and treatment of
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